7. Bussel JB et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. 50th American Society of Hematology Annual Meeting and Exposition; Abstract 3431
13. Letter to DAC members from Dr Raymond SM Wong, Consultant, Division of Haematology, Department of Medicine & Therapeutics. Prince of Wales Hospital. Received through email on 4 Jan, 2012.
14. Letter to Secretary of DAC from Dr Albert Lie, Convenor of the Haematology Working Group,. Queen Mary Hospital. Dated on 6 December 2011.
15. FDA drug safety communication: modified risk evaluation and mitigation strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag). 12 Jun 2011.
16. Power point presentation - TPO receptor agonists in Asian chronic ITP patients – our local experience in HK. Dr Raymond SM Wong. Department of Medicine & Therapeutics, Prince of Wales Hospital. The Chinese University of Hong Kong. 24 February 2012.